| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ObsEva | Linzagolix - (open label) | Severe adenomyosis | Phase 3 | Oral | Women's Health | |
| ObsEva | Linzagolix (OBE2109) - (EDELWEISS 3) | Endometriosis | Phase 3 | Oral | Women's Health | |
| ObsEva | Linzagolix (OBE2109) - (EDELWEISS 2) | Endometriosis | Phase 3 | Oral | Women's Health | |
| ObsEva | Nolasiban (OBE001) - IMPLANT 4 | Improving IVF outcomes | Phase 3 | Oral | Women's Health | |
| ObsEva | Nolasiban (OBE001) - (IMPLANT2) | In Vitro Fertilization (IVF) | Phase 3 | Oral | Women's Health | |
| ObsEva | Ebopiprant | Pre-term labor | Phase 2b | Oral | Women's Health | |
| Ocugen, Inc. | OCU400 (AAV-NR2E3) | Retinitis Pigmentosa | BLA Filing | Data Released | Subretinal injection | Genetic Disorder |
| Ocugen, Inc. | NeoCart (autologous chondrocyte-derived neocartilage) | Repair of the knee cartilage | Phase 3 | Trial Planned | Intra-articular | Orthopedic |